Chronic Kidney Disease

Novel Peptide-Based ESA Promising

BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises hemoglobin levels in anemic CKD patients and maintains stable hemoglobin levels in hemodialysis patients who switch to the drug from epoetin alfa, data suggest.

Once Monthly C.E.R.A. Found Beneficial

BARCELONA—Once-monthly dosing of continuous erythropoietin receptor activator (C.E.R.A.) maintains stable hemoglobin levels in CKD patients regardless of age, gender, or comorbidities, according to study data presented here at the 44th Congress of the European Renal Association-European Dialysis and Transplant Association.

Lowering Homocysteine Not Beneficial

Using high doses of folic acid and B vitamins to lower elevated homocysteine levels in patients with advanced CKD (ACKD) or end-stage renal disease (ESRD) does not improve survival or decrease the incidence of vascular disease, data show.

How to Manage Vitamin D Deficiency

The active forms of vitamin D—calcitriol, paricalcitol, and doxercalciferol—which also are known as vitamin D receptor activators (VDRAs), have been largely used in nephrology only as a treatment for secondary hyperparathyroidism, an elevation in parathyroid hormone (PTH) due to renal failure.

Untreated Anemia Increases Morbidity

CHICAGO—Diabetics with CKD whose anemia is untreated have twice the overall risk of CVD-related hospitalizations, according to data reported at the 67th Scientific Sessions of the American Diabetes Association.

Next post in News